Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687986 | 0.92 | OPRD1 (0.71) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL1743520 | 0.90 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL1894961 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL12588957 | 0.84 | OPRD1 (0.58) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL12929716 | 0.84 | OPRD1 (0.58) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL17280918 | 0.84 | OPRD1 (0.58) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL4705017 | 0.83 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL30340025 | 0.83 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL29389298 | 0.83 | OPRD1 (0.69) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL3178079 | 0.83 | OPRD1 (0.60) | OPRD1OPRM1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3151817-B1 | SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | SCRIPPS RESEARCH INST (US) | 2021-03-03 | — | — | EP | claimed |
| US-20200345722-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200345723-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200093819-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL, INC. | 2020-03-26 | — | — | US | claimed |
| US-20200093820-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2020-03-26 | — | — | US | claimed |
| US-20190029972-A1 | SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-31 | — | — | US | claimed |
| EP-3326617-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | Collegium Pharmaceutical, Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| US-20180028528-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. | 2018-02-01 | — | — | US | claimed |
| US-20180028529-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. | 2018-02-01 | — | — | US | claimed |
| US-9763879-B2 | Oral film containing opiate enteric-release beads | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2017-09-19 | — | — | US | claimed |
| US-20040043990-A1 | Method of treatment | JACKSON KAREN (GB) | 2004-03-04 | — | — | US | claimed |
| WO-2003103679-A1 | USE OF DEVAZEPIDE IN COMBINATION WITH AN OPIOID ANALGESIC FOR POTENTIATING THE EFFECT OF THE ANALGESIC | ML LABORATORIES PLC (GB) | 2003-12-18 | — | — | WO | claimed |
| WO-2003086409-A1 | THE USE OF DEVAZEPIDE AS ANALGESIC AGENT | ML LABORATORIES PLC (GB) | 2003-10-23 | — | — | WO | claimed |
| WO-2003080066-A1 | USE OF DEVAZEPIDE FOR THE TREATMENT OF CONSTIPATION | ML LABORATORIES PLC (GB) | 2003-10-02 | — | — | WO | claimed |
| US-20030153592-A1 | Method | INNOVATA PLC (GB) | 2003-08-14 | — | — | US | claimed |
| WO-2003061632-A1 | METHOD OF TREATMENT OF A PATIENT REQUIRING ANALGESIA | ML LABORATORIES PLC (GB) | 2003-07-31 | — | — | WO | claimed |
| US-20030139396-A1 | Constipation; administering devazepide | ML LABORATORIES PLC (GB) | 2003-07-24 | — | — | US | claimed |
| CN-1069544-C | Thebaica giving-up vaccinum for man | KUNMING BIOLOG TECH ENGINEERIN (CN) | 2001-08-15 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| CN-1196955-A | Thebaica giving-up vaccinum for man | KUNMING BIOLOG TECH ENGINEERIN (CN) | 1998-10-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190029972-A1 | SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | HAX1, CYP2F1, CYP4X1 | OPRD1 910/4885OPRM1 237/4885OPRK1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.